Novelstem International CorpOTC Pink - Current Information:NSTM
- LAST PRICE0.0600
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0601/ 100
- Ask / Lots0.0790/ 134
- Open / Previous Close0.0000 / 0.0600
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Time | Volume | NSTM |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Novelstem International Corp | 2.8M | -0.7x | --- |
ENDRA Life Sciences Inc | 2.7M | -0.1x | --- |
Evolutionary Genomics Inc | 3.0M | -1.3x | --- |
Transcode Therapeutics Inc | 3.0M | 0.0x | --- |
Windtree Therapeutics Inc | 2.6M | -0.6x | --- |
Aclarion Inc | 2.8M | 0.0x | --- |
Company Information
NovelStem International Corp. is a development-stage biotechnology holding company focused on stem cell-based technology. The Company's primary assets are NewStem Ltd (NewStem) and NetCo Partners (NetCo). NewStem focuses on the development and commercialization of diagnostic technology that can predict patients’ anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. NewStem is principally focused on utilizing proprietary human Pluripotent Stem Cells (hPSCs) and Haploid human Pluripotent Stem Cells (HhPSCs) in the development of diagnostic and therapeutic products in oncology. Its NewStem Software Diagnostic Device (NSDD) is a bioinformatics-based software medical device platform that provides oncologists with information regarding the presence of mutations in tumors, which may confer patient resistance to certain anti-cancer drugs. NetCo is a media business interest which owns Net Force, a book publishing franchise.
Contact Information
- Headquarters
- 2255 Glades Rd, Ste 237 WBOCA RATON, FL, United States 33431
- Phone
- 561-998-8000
- Fax
- 561-998-2974
Executives
- Executive Chairman of the Board, Chief Executive Officer, President
- Jan Loeb
- Chief Financial Officer, Vice President, Secretary
- Christine Jenkins
- Director
- Jerry Wolasky
- Independent Director
- Tracy Clifford
- Independent Director
- Eric Richman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.8M |
|---|---|
Revenue (TTM) | $12.0K |
Shares Outstanding | 46.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.23 |
EPS | $-0.09 |
Book Value | $-0.04 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 234.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -29,381.67% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
